Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must satisfy the following criteria at study entry:~* A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of age at time of first vaccination and NOT have already received a dose of vaccine against diphtheria, tetanus or pertussis or Hemophilus influenzae type B and must be \> 28 days of age at screening.~* Signed informed consent or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~All subjects must satisfy the following criteria at the start of the extension phase:~* Subjects who were enrolled and who received at least one vaccine dose in the primary trial phase.~* Subjects who were present for Visit 35 on or before 30 September 2013.~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. return for follow-up visits) should be enrolled in the study.~Exclusion Criteria:~The following criteria should be checked at the time of study entry. If any apply, the subject must not be included in the study:~* Acute disease at the time of enrollment.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality.~* Anemia associated with clinical signs or symptoms of decompensation or hemoglobin ≥ 5.0 g/dL.~* Major congenital defects.~* History of allergic reactions, significant IgE-mediated events or anaphylaxis to previous immunizations.~* Children with a past history of a neurological disorder or atypical febrile seizure.~* Children with malnutrition requiring hospital admission.~* Children currently meeting the criteria for HIV disease of Stage III or Stage IV severity as defined by the World Health Organization.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to a drug or vaccine that is not licensed for that indication with the exception of studies with the objective of improving the drug treatment or clinical management of severe malaria disease.~* Use of a drug or vaccine that is not approved for that indication other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Previous participation in any other malaria vaccine trial.~* Receipt of a vaccine within the preceding 7 days.~* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.~* Any other findings that the investigator feels would result in data collected being incomplete or of poor quality

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 17 Months
- Healthy Volunteers: t

Study Arms:
- GSK257049 [5-17M] Group (Type: EXPERIMENTAL): Male or female children between and including 5 to 17 months of age \[5-17M\], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
- GSK257049 [6-12W] Group (Type: EXPERIMENTAL): Male or female children between and including 6 to 12 weeks of age \[6-12W\], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
- VeroRab Comparator [5-17M] Group (Type: ACTIVE_COMPARATOR): Male or female children between and including 5 to 17 months of age \[5-17M\], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
- Menjugate Comparator [6-12W] Group (Type: EXPERIMENTAL): Male or female children between and including 6 to 12 weeks of age \[6-12W\], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete